Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01480843 · ClinicalTrials.gov registry record · Phase 4
Simplified Insulin Protocol Using Lantus in Elderly
A Phase 4 study, sponsored by Joslin Diabetes Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 65
- Enrollment target
NCT01480843 is a Phase 4 study that has completed, run by Joslin Diabetes Center. The registered enrollment target is 65 participants.
The verdict
NCT01480843, a Phase 4 study, has completed, sponsored by Joslin Diabetes Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 65 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if simplifying your diabetes treatment by decreasing number of insulin injections, with the help of a long acting insulin called glargine, can decrease the episodes of low blood glucose.
Interventions
- DRUG Glargine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2011-06 |
| Est. Completion | 2015-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01480843
The ClinicalTrials.gov registry entry for NCT01480843 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Joslin Diabetes Center, which has 73 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Glargine is the first listed.
NCT01480843 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01480843 about?
NCT01480843 is a clinical study titled "Simplified Insulin Protocol Using Lantus in Elderly". The purpose of this study is to find out if simplifying your diabetes treatment by decreasing number of insulin injections, with the help of a long acting insulin called glargine, can decrease the episodes of low blood glucose.
What is the current status of trial NCT01480843?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 65 participants. The study started on 2011-06. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01480843?
The interventions under investigation include: Glargine (DRUG).
Who is sponsoring clinical trial NCT01480843?
This trial is sponsored by Joslin Diabetes Center, which has 73 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.